FDA let artificial-blood trials continue despite risks
Wednesday, April 30, 2008 - 13:51
in Health & Medicine
A report that pools data from 16 studies concludes that the FDA should have halted research years earlier because of increased incidence of heart attacks and deaths. Despite evidence that a group of experimental blood substitutes nearly tripled the risk of heart attacks and caused a 30% increase in deaths, the Food and Drug Administration continued to approve some clinical trials of the products, researchers said Monday.
Read the whole article on LA Times - Science
More from LA Times - Science
Related
- ACCORD clinical trial publishes resultsFri, 6 Jun 2008, 17:35:45 EDT
- Common COPD medications linked with increased risk of CV death, heart attackTue, 23 Sep 2008, 16:43:40 EDT
- Risk of sudden cardiac death appears increased within 30 days of heart attackTue, 4 Nov 2008, 16:36:13 EST
- When statins aren't enough: New trial drug points to better management of coronary heart diseaseThu, 8 May 2008, 14:22:20 EDT
- Study finds link between atrial fibrillation and an increased risk of death in diabetic patientsWed, 11 Mar 2009, 20:37:45 EDT